Cannabis C corporations in light of marijuana rescheduling

Cannabis businesses have often chosen C corporation status for a simple reason: Section 280E makes entity choice unusually important.

Because marijuana’s Schedule I status has meant state-legal cannabis businesses cannot deduct many ordinary and necessary business expenses under §162, wages, rent, utilities, marketing and other operating costs are often disallowed by §280E. Cost of goods sold (COGS) remains available as an adjustment to gross income rather than a deduction.

Against that backdrop, the 21% C corporation rate could be easier to absorb than passing §280E-inflated income through to owners at higher individual rates. But that choice has always carried tradeoffs, including possible double taxation when earnings are distributed or shares are sold and losses trapped at the corporate level. Now, medical marijuana rescheduling has changed the conversation. Tax professionals should not assume that every cannabis client must change entity structure, but they also should not assume that the old analysis still applies to every operator.

Quick take

Many cannabis businesses chose C corporations because §280E made the 21% corporate rate more attractive than passthrough treatment, especially when earnings were being retained for growth. For investor-backed operators, the corporate form also offered practical business advantages. Rescheduling may remove §280E as a bar to deductions and credits for marijuana moved to Schedule III, but adult-use and nonqualifying activity will still require careful planning. Tax pros should revisit entity choice based on license status, activity mix, cash needs and long-term exit plans.

Why cannabis operators often chose C corporations

Section 280E disallows deductions and credits for a business trafficking in Schedule I or II controlled substances prohibited under federal or applicable state law, even if the activity is legal under state law. For cannabis businesses, that has meant federal taxable income can far exceed economic income.

A C corporation does not avoid §280E; it simply applies the corporate rate at the entity level to the resulting taxable income. A passthrough entity may push §280E-inflated income onto owners’ individual returns, even when cash is reinvested. A C corporation pays tax directly, and owners are taxed later when dividends are paid or stock is sold.

This is not a perfect solution; it is a rate-and-structure tradeoff that has often fit a capital-intensive, highly regulated industry with limited deductions and frequent investor needs.

The C corporation is not a §280E workaround

Tax professionals should be clear: C corporation status does not eliminate §280E. If §280E applies, it applies to the corporation. Ordinary operating expenses may still be nondeductible, and effective tax rates can remain high relative to cash profit. A later distribution or sale still triggers shareholder-level tax.

The C corporation decision is best framed as: What rate applies, where and when? That framing helps clients understand why a structure that usually creates double taxation might still be chosen for a cannabis business.

Medical marijuana rescheduling changes the planning question

Federal rescheduling has moved forward for certain medical marijuana activity, but §280E planning is not fully settled. The Department of Justice (DOJ) final order places Food and Drug Administration (FDA)-approved marijuana products and state-licensed medical marijuana products in Schedule III, while marijuana outside those qualifying medical channels remains in Schedule I. Treasury and the IRS have said rescheduling generally removes §280E as a bar to deductions and credits for businesses that no longer traffic in Schedule I or II controlled substances, but forthcoming guidance is expected to address transition timing, expense allocation and businesses with multiple activities.

This means entity choice will become more fact-specific. Tax pros may need to separate clients into planning buckets:

➔ State-licensed medical marijuana operator: Does reduced §280E exposure change the value of C corporation status?
➔ Adult-use operator: Does continuing §280E pressure still point toward a C corporation?
➔ Mixed medical/adult-use operator: Are accounting systems strong enough to separate activities and expenses if tax treatment diverges?
➔ Growing or investor-backed operator: Does the C corporation still fit the capital, governance and exit plan?

Clients may hear “rescheduling” and assume the tax problem is solved. The tax pro’s role is to slow the conversation down and identify which activity, entity, license and tax year are actually affected.

Cannabis entity choice pressure test

Before recommending a new structure, pressure-test the current facts:

• Medical, adult-use or both? Rescheduling and §280E relief may not apply evenly across activities.
• What licenses are held? Eligibility for any future §280E relief will likely turn on the specific framework and product mix.
• Are earnings distributed or reinvested? Double taxation is less painful when earnings are retained, more painful when owners need cash.
• Is outside capital or a sale part of the growth plan? C corporations may still offer practical advantages for capital raising and exits.

The choice between a C corporation and a passthrough entity depends on residual §280E exposure, available cash flow and the client’s long-term business plan.

Tradeoffs that remain after rescheduling

Even if §280E relief becomes available, C corporation fundamentals do not change:

• Double taxation. Entity-level tax plus shareholder-level tax on distributions or stock sales.
• Trapped losses. Losses generally stay in the corporation and do not flow through to owners.
• Non-trivial conversions. Moving from C corporation to passthrough form often triggers tax and state-law complexity.
• Mixed activities and accounting. If some operations remain subject to §280E, strong books and defensible allocations will be critical.

What tax pros should tell cannabis clients now

Rescheduling may change the tax math, but it does not automatically answer the entity-choice question. For many operators, C corporation status may remain the best fit because of investor expectations, retained earnings, multistate growth or continuing §280E exposure. For others, especially qualifying medical operators, the benefit of remaining a C corporation may need a fresh look once IRS guidance are in place.

This is a moment to review entity structure rather than to assume. A solid review should cover tax rates, expected distributions, licensing, activity mix, accounting systems and exit strategy.

Cannabis tax planning is not getting simpler; it is getting more specific. NATP members serving or entering the cannabis space should build technical foundations now and monitor developments as guidance is issued.